*May 2014 – for immediate release. Further information: Chris Pockett, +44 (0) 1453 524133*

**Renishaw *neuromate*® frameless Gen II cleared by the FDA**

Renishaw is pleased to announce that the U.S. Food and Drug administration (FDA) has issued clearance to market the *neuromate*® frameless Gen II stereotactic robotic system.

Dr. Abed Hammoud, CEO of Renishaw Mayfield SA said, “We are excited to launch our newest generation *neuromate*® robotic system in the US, which is the largest global market for medical devices. Our clinical solutions and technical support teams are looking forward to working with some of the leading centres in the US and establishing robotics in the Neuro operating room.”

- ENDS –

Notes to editors

Renishaw is a global company with core skills in measurement, motion control, spectroscopy, neurosurgical products and precision machining. The company has over 3,300 employees based at offices in 32 countries, and is listed on the London Stock Exchange (LSE:RSW) where it is a constituent of the FTSE 250.

For more information visit [www.renishaw.com](http://www.renishaw.com)